Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its presence in the pharmaceutical AI transformation with the PDAOAI platform, an evidence-interrogation system designed to extract testable hypotheses from the vast body of TGF-β signaling research. According to a recent announcement, PDAOAI indexes more than 125,000 PubMed abstracts on TGF-β signaling, allowing researchers to interrogate the evidence and build transparent, auditable chains from question to hypothesis.
The platform addresses a core challenge in biotech research: reducing training-set bias and moving away from black-box predictive models. Instead of relying on traditional AI that replicates historical datasets, PDAOAI uses a retrieval-and-interrogation approach, enabling researchers to identify patterns and generate hypotheses with direct links to source evidence. This hypothesis-first methodology is crucial as regulatory agencies raise expectations around data integrity and traceability.
Recent industry coverage has placed Oncotelic alongside companies like Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations. The broader context is a structural transition in pharmaceutical research and manufacturing, where manual processes and isolated datasets are no longer sufficient. The industry is shifting from retrospective audits toward continuous, AI-enabled monitoring systems, while drug discovery benefits from large-scale biomedical data and tools to interrogate it at scale.
Oncotelic’s PDAOAI platform fits this transformation by providing a way to navigate the rapidly expanding scientific literature. As the press release notes, “both shifts reflect a common underlying reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory expectations demand continuous, defensible documentation.”
For researchers and investors, the significance lies in PDAOAI’s potential to improve the reproducibility and transparency of early-stage drug discovery. By focusing on TGF-β signaling—a pathway implicated in cancer, fibrosis, and immune regulation—the platform targets a critical area of biomedical research. The ability to generate testable, auditable hypotheses could accelerate the identification of novel therapeutic targets and reduce the risk of bias in preclinical research.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, fibrosis, and inflammatory diseases. The company’s newsroom at ibn.fm/OTLC provides updates on its developments.
